Profile data is unavailable for this security.
About the company
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
- Revenue in USD (TTM)66.75m
- Net income in USD26.16m
- Incorporated2000
- Employees46.00
- LocationMEI Pharma Inc11455 El Camino Real, Suite 250SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 369-7100
- Fax+1 (302) 655-5049
- Websitehttps://www.meipharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lyra Therapeutics Inc | 1.68m | -68.88m | 18.00m | 109.00 | -- | 0.2322 | -- | 10.71 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
Talphera Inc | 651.00k | -14.31m | 18.01m | 15.00 | -- | 1.10 | -- | 27.67 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
Pharmacyte Biotech Inc | 0.00 | -14.82m | 18.34m | 2.00 | -- | 0.5894 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Bioxytran Inc | 0.00 | -4.30m | 18.37m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 18.69m | 8.00 | -- | 1.86 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Synlogic Inc | 3.21m | -73.22m | 18.73m | 6.00 | -- | 1.40 | -- | 5.84 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
Iterum Therapeutics PLC | 0.00 | -35.58m | 19.04m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 19.14m | 55.00 | -- | 0.642 | -- | 1.13 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
MEI Pharma Inc | 66.75m | 26.16m | 19.32m | 46.00 | 0.7388 | 0.3787 | 0.7289 | 0.2895 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Lumos Pharma Inc | 1.53m | -37.13m | 19.40m | 33.00 | -- | 1.11 | -- | 12.72 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 19.63m | 4.00 | -- | 2.88 | -- | 301.94 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
Vincerx Pharma Inc | 0.00 | -38.25m | 20.07m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
Longeveron Inc | 978.00k | -21.62m | 20.25m | 23.00 | -- | 2.64 | -- | 20.71 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
Polypid Ltd | 0.00 | -24.25m | 20.34m | 59.00 | -- | 2.85 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Forte Biosciences Inc | 0.00 | -32.14m | 20.37m | 11.00 | -- | 0.7093 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Holder | Shares | % Held |
---|---|---|
Anson Funds Management LPas of 31 Mar 2024 | 1.09m | 16.41% |
Cable Car Capital LLCas of 31 Mar 2024 | 611.44k | 9.18% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 388.01k | 5.82% |
Acadian Asset Management LLCas of 31 Mar 2024 | 211.73k | 3.18% |
Renaissance Technologies LLCas of 31 Mar 2024 | 143.09k | 2.15% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 81.58k | 1.22% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 71.59k | 1.07% |
Carlson Capital LPas of 31 Mar 2024 | 64.00k | 0.96% |
Geode Capital Management LLCas of 31 Mar 2024 | 52.43k | 0.79% |
Macquarie Investment Management Business Trustas of 31 Mar 2024 | 30.00k | 0.45% |